← Back to Search

Alkylating agents

DCdP for Multiple Myeloma (DCDP Trial)

Phase 2

Waitlist Available

Research Sponsored by Canadian Myeloma Research Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 36 months of from randomization

Awards & highlights

DCDP Trial Summary

This trial is testing a new treatment for relapsed and refractory multiple myeloma. It consists of two drugs, with or without a third drug.

Eligible Conditions

Multiple Myeloma

DCDP Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 36 months of from randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~36 months of from randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months of from randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression-Free Survival

DCDP Trial Design

2Treatment groups

Experimental Treatment

Group I: ARM BExperimental Treatment1 Intervention

Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle. Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles. Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly. Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle.

Group II: ARM AExperimental Treatment1 Intervention

Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle. Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles. Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly. Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

DCdP

2017

Completed Phase 2

~120

DCd+P

2017

Completed Phase 2

~120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Canadian Myeloma Research GroupLead Sponsor

6 Previous Clinical Trials

383 Total Patients Enrolled

6 Trials studying Multiple Myeloma

383 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the geographical reach of this investigation?

"The medical trial is conducted in 11 different facilities across the country, including Saint John Regional Hospital, CancerCare Manitoba and Princess Margaret Cancer Centre."

Answered by AI

Is this experiment open to new participants?

"Sadly, this clinical trial is no longer enrolling participants. Initially posted on October 25th 2017 and last edited on July 18th 2022, it has since been superseded by 807 studies for multiple myeloma and 1337 trails for DCdP with active recruitment efforts."

Answered by AI

How many participants are actively taking part in this research initiative?

"At present, this trial is not actively enrolling participants. This investigation was first posted on 25th October 2017 and last updated 18th July 2022. For those seeking alternative trials, there are 807 studies with open enrollment for multiple myeloma patients and 1337 investigations looking to recruit individuals with DCdP."

Answered by AI

To what extent have researchers explored the potential of DCdP?

"Currently, 1337 active trials are examining DCdP with 272 of those studies in their final phase. Philadelphia, Pennsylvania is a leader in this research field with 42594 sites running clinical trials for DCdP across the globe."

Answered by AI

To what degree has DCdP proven efficacious in treating medical ailments?

"DCdP has been known to successfully treat synovitis, ophthalmia, sympathetic and lung cancers."

Answered by AI

Is DCdP a risk-free option for individuals?

"The safety of DCdP has been assessed by our team at Power and given a score of 2 due to the limited clinical data suggesting its efficacy, but some existing evidence validating its security."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

2017. "A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03215524.